Deterioration of executive functioning in chronic ecstasy users: Evidence for multiple drugs effects

Current Drug Abuse Reviews

Volumn 3, Issue 3, 2010, Pages 129-138

  Verbaten, Marinus N ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Dose response effects; Ecstasy; Meta analysis; Working memory

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; ALCOHOL; CANNABIS; COCAINE; ECSTASY; LYSERGIDE; NICOTINE; PSYCHOTROPIC AGENT; UNCLASSIFIED DRUG; PSYCHEDELIC AGENT;

ARTICLE; ATTENTION; CENTRAL EXECUTIVE; COGNITION; DRUG ABUSE; DRUG EFFECT; EXECUTIVE FUNCTION; HUMAN; INHIBITION (PSYCHOLOGY); LONG TERM MEMORY; MENTAL DETERIORATION; PRIORITY JOURNAL; REGRESSION ANALYSIS; SCORING SYSTEM; WORKING MEMORY; ADDICTION; ANIMAL; DOSE RESPONSE; META ANALYSIS; PATHOPHYSIOLOGY; REVIEW; SHORT TERM MEMORY; TIME;

ANIMALS; ATTENTION; DOSE-RESPONSE RELATIONSHIP, DRUG; EXECUTIVE FUNCTION; HALLUCINOGENS; HUMANS; MEMORY, SHORT-TERM; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; SUBSTANCE-RELATED DISORDERS; TIME FACTORS;

EID: 79953793176     PISSN: 18744737     EISSN: 18744745     Source Type: Journal    
DOI: 10.2174/1874473711003030129     Document Type: Article

References (53)

1. Verbaten MN. Specific memory deficits in ecstasy users? The results of a meta-analysis. Hum Psychopharm 2003; 18: 281-90.
2. Laws KR, Kokkalis J. Ecstasy (MDMA) and memory function: a meta-analytic update. Hum Psychopharm 2007; 22: 381-8.
3. Zakzanis KK, Campbell Z, Jovanovski D. The neuropsychology of ecstasy (MDMA) use: a quantitative review. Hum Psychopharm 2007; 22: 427-35.
4. Parsons OA, Nixon SJ. Cognitive functioning in sober social drinkers: a review of the research since 1986. J Stud Alcohol 1998; 59: 180-90.
5. Baddeley A, Hitch G. In: Bower, GH, Ed. The psychology of Learning and Motivation. New-York, Academic Press 1974; 47-89.
6. Engle RW, Tuholski S, Laughlin JE, Conway ARA. Working memory, short-term memory, and general fluid intelligence: A latent variable approach. J Exp Psychol Gen 1999; 125: 309-31.
7. Miyake A, Friedman NP, Emerson MJ, Wizski AH, Howerter A. The unity and diversity of executive functions and their contributions to complex "Frontal lobe" tasks: A latent variable analysis. Cogn Psychol 2000: 41: 49-100.
8. Fisk JE, Sharp CA. Age-related impairment in executive functioning: updating, inhibition, shifting and access. J Clin Exp Neuropsychol 2004; 26: 874-90.
9. Solowij N, Battisti R. The chronic effects of cannabis on memory in humans: a review. Curr Drug Abuse Rev 2008; 1: 81-98.
10. Sim ME, In KL, Streeter CC, et al. Cerebellar gray matter volume correlates with duration of cocaine use in cocaine-dependent subjects. Neuropsychopharmacol 2007; 32: 2229-37.
11. Sim T, Simon SL, Domier CP, Richardson K, Rawson RA, Ling W. Cognitive deficits among methamphetamine users with Attention Deficit Hyperactivity Disorder symptomatology. J Add Dis 2002; 21: 75-89.
12. Andrès P. Frontal cortex as the central executive of working memory: time to revise our view. Cortex 2003; 39: 871-95.
13. Lipsey MW, Wilson DB. Practical meta-analysis. Thousand Oaks (CA): Sage Publications 2000.
14. Rosenthal R. The 'file drawer problem' and tolerance for null results. Psychol Bull 1979; 86: 639-41.
15. Croft RJ, Mackay AJ, Mills ATD, Gruzelier JGH. The relative contributions of ecstasy and cannabis to cognitive impairment. Psychopharm 2001; 153: 373-9.
16. Heffernan TM, Jarvis H, Rodgers J, Scholey AB, Ling J. Prospective memory, everyday cognitive failure and central executive function in recreational users of ecstasy. Hum Psychopharm 2001; 16: 607-12.
17. Montgomery C, Fisk JE, Newcombe R, Murphy PN. The differential effects of ecstasy/polydrug use on executive components: shifting, inhibition, updating and access to semantic memory. Psychopharm 2005; 182: 262-76.
18. Reneman L, Schilt T, de Win MM, et al. Memory function and serotonin transporter promoter gene polymorphism in ecstasy (MDMA) users. J Psychopharm 2006; 20: 389-90.
19. De Sola Llopis S, Miguelez-Pan M, Pea-Casanova J, et al. Cognitive performance in recreational ecstasy polydrug users: a two-year follow-up study. J Psychopharm 2008; 22: 498-510.
20. Morgan MM. Recreational use of "Ecstasy" (MDMA) is associated with elevated impulsivity. Neuropsychopharm 1998; 19: 252-64.
21. Fox HC, Parrott AC, Turner JJD. Ecstasy use: cognitive deficits related to dosage rather than self-reported problematic use of the drug. J Psychopharm 2001; 15: 273-81.
22. Alting von Geusau N, Stalenhoef P, Huizinga M, Snel J, Ridderinkhof KR. Impaired executive function in male MDMA ("ecstasy") users. Psychopharm 2004; 175: 331-41.
23. Dafters RI. Chronic ecstasy (MDMA) use is associated with deficits in task-switching but not inhibition or memory updating executive functions. Drug Alc Depend 2006; 83: 181-4.
24. Lamers CTJ, Bechara A, Rizzo M, Ramaekers JG. Cognitive function and mood in MDMA/THC users. THC users and non-drug using controls. J Psychopharm 2006; 20: 302-11.
25. Reay JL, Hamilton C, Kennedy DO, Scholey AB. MDMA polydrug users show process-specific central executive impairments coupled with impaired social and emotional judgement processes. J Psychopharm 2006; 20: 385-8.
26. Smith RM, Tivarus M, Campbell HL, Hillier A, Beversdorf DQ. Apparent transient effects of recent "Ecstasy" use on cognitive performance and extrapyramidal signs in human subjects. Cog Behav Neurol 2006; 19: 157-64.
27. Gamma A, Brandeis D, Brandeis R, Vollenweider FX. The P3 in 'ecstasy' polydrug users during response inhibition and execution. J Psychopharm 2005; 19: 504-12.
28. Dafters RI. Impulsivity, inhibition and negative priming in ecstasy users. Add Beh 2006; 31: 1436-41.
29. Hoshi R, Mullins K, Boundy C, Brignell C, Piccini P, Curran HV. Neurocognitive function in current and ex-users of ecstasy in comparison to both matched polydrug-using controls and drug- naïve controls. Psychopharm 2007; 194: 371-9.
30. Quednow BB, Kühn KU, Hoppe C, et al. Elevated impulsivity and impaired decision-making cognition in heavy users of MDMA ("Ecstasy"). Psychopharm 2007; 189: 517-30.
31. Fisk JE, Montgomery C. Evidence for selective executive function deficits in ecstasy/polydrug users. J Psychopharm 2009; 23: 40-50.
32. Fox HC, McLean A, Turner JJD, Parrott AC, Rogers R, Sahakian BJ. Neuropsychological evidence of a relatively selective profile of temporal dysfunction in drug-free MDMA ("ecstasy") polydrug users. Psychopharmacology 2002; 162: 203-14.
33. Morgan MJ, McFie L, Fleetwood LH, Robinson JA. Ecstasy (MDMA): are the psychological problems associated with its use reversed by prolonged abstinence? Psychopharmacol 2002; 159: 294-303.
34. Thomasius R, Petersen K, Buchert R, et al. Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users. Psychopharm 2003; 167: 85-96.
35. Wareing M, Fisk JE, Murphy P, Montgomery C. Verbal working memory deficits in current and previous users of MDMA. Hum Psychopharmacology Clin Exp 2004a; 19: 225-34.
36. Wareing M, Murphy PN, Fisk JE. Visuospatial memory impairments in users of MDMA ('ecstasy'). Psychopharmacol 2005; 173: 391-7.
37. Quednow BB, Jessen F, Kühn KU, Maier W, Daum I, Wagner M. Memory deficits in abstinent MDMA (ecstasy) users: neuropsychological evidence of frontal dysfunction. J Psychopharm 2006; 20: 373-84.
38. Golding JF, Groome DH, Rycroft N, Denton Z. Cognitive performance in light current users and ex-users of ecstasy (MDMA) and controls. Am J Drug Alc Abuse 2007; 33: 301-7.
39. Rendell PG, Gray TJ, Henry JD. Prospective memory impairment in "ecstasy" (MDMA) users. Psychopharm 2007; 194: 497-504.
40. Roiser JP, Rogers RD, Sahakian BJ. Neuropsychological function in ecstasy users: a study controlling for polydrug use. Psychopharm 2007; 189: 505-16.
41. Wareing M, Fisk JE, Montgomery C, Murphy PN, Chandler M. Information processing speed in ecstasy (MDMA) users. Hum Psychopharm Clin Exp 2007; 22: 81-8.
42. Schilt T, de Win MM, Koeter M, Jager G, Korf DJ, van den Brink W, Schmand B. Cognition in novice ecstasy users with minimal exposure to other drugs. Arch Gen Psychiatry 2007; 64: 728-36.
43. Kalechstein AD, De La Garza II R, Mahoney III JJ, Fantegrossi WE, Newton TF. MDMA use and neurocognition: a meta-analytic review. Psychopharm 2007; 189: 531-7.
44. Ricaurte GA, DeLanney LE, Irwin I, Langston JW. Toxic effects of MDMA on central serotonergic neurons in the primate: importance of route and frequency of drug administration. Brain Res 1988; 446: 165-8.
45. Jager G, de Win MM, Vervaeke HK, et al. Incidental use of ecstasy: no evidence for harmful effects on cognitive brain function in a prospective fMRI study. Psychopharm 2007; 193: 403-14.
46. Little KY, Ramssen E, Welchko R, Volberg V, Roland CJ, Cassin B. Decreased brain dopamine cell numbers in human cocaine users. Psychiatr Res 2009; 168(3): 173-80.
47. Wilson JM, Kish SJ. The vesicle monoamine transporter, in contrast to the dopamine transporter, is not altered by chronic cocaine self-administration in the rat. J Neurosci 1996;16: 3507-10.
48. Matochik JA, London ED, Eldreth DA, Cadet JL, Bolla KI. Frontal cortical tissue composition in abstinent cocaine users. Neuroimage 2003; 19: 1095-102.
49. Rogers RD, Everitt BJ, Baldacchino A. Dissociable deficits in the decision-making cognition of chronic methamphetamine abusers, patients with focal damage to prefrontal cortex, and tryptophan- depleted normal volunteers: evidence for monoaminergic mechanisms. Neuropsychopharm 1999; 20: 322-39.
50. Volkow ND, Chang L, Chang GJ, et al. Low level of brain dopamine D2 receptors in methamphetamine abusers: association with metabolism in the orbito-frontal cortex. Am J Psychiatry 2001; 158: 2015-21.
51. Beveridge TJR, Gill KE, Hanlon CA, Porrino LJ. Parallel studies of cocaine-related neural and cognitive impairment in humans and monkeys. Phil Trans R Soc B 2008; 363: 3257-66.
52. Halpern JH, Pope HG. Do hallucinogens cause residual neuropsychological toxicity? Drug Alc Dep 1999; 53: 247-56.
53. Young CR. Sertraline treatment of hallucinogen persisting perception disorder. J Clin Psychiatr 1997; 58: 85.